摘要
骨肉瘤(Osteosarcoma, OS)是一种原发性骨恶性肿瘤,在儿童和青少年中发病率较高。OS受累细胞和组织表现出耐药特性,预后仍较差;因此,迫切需要新的治疗方法。MicroRNAs (miRNAs)表达模式已被证实参与了OS的发病机制。miRNAs是小的非编码RNA分子,在转录后水平负调控基因表达。有大量的miRNAs在疾病的发病、疾病进展的调节和对治疗的反应中具有关键作用。目前,最近发布的Human MicroRNA Disease Database 3.0版本(HMDD v3.0)报告称,OS中有194个miRNAs调控异常,可能参与肿瘤细胞的增殖、迁移、侵袭和上皮-间充质转化。癌基因和抑癌miRNAs之间的平衡对OS细胞行为的最终命运至关重要。此外,在OS的启动或发展过程中,miRNAs网络可能协同作用,诱导致癌或肿瘤抑制特性。这些miRNAs的上调或下调会影响治疗期间或之后的疾病状态。到目前为止,在OS疾病中已经发现了40多个具有致癌或肿瘤抑制特性的miRNAs,研究者正在试图建立一个有利于OS治疗的适当水平的此类miRNAs。miRNAs在骨肉瘤发病机制中的作用及其治疗潜力是本文的参考点。
关键词: 骨肉瘤,MicroRNA,转移,血管生成,靶向治疗,自噬。
Current Molecular Medicine
Title:MicroRNAs Implications in the Onset, Diagnosis, and Prognosis of Osteosarcoma
Volume: 21 Issue: 7
关键词: 骨肉瘤,MicroRNA,转移,血管生成,靶向治疗,自噬。
摘要: Osteosarcoma (OS) is a primary bone malignancy, which has a high incidence in children and adolescents. The affected cells and tissues show the properties of drug-resistance and the prognosis remains poor in OS; therefore, there is an essential need for novel therapeutic approaches. MicroRNAs (miRNAs) expression pattern has been established to be involved in the pathogenesis of OS. miRNAs are small non-coding RNA molecules, which negatively regulate gene expression at the post-transcriptional level. There are copious miRNAs that have a critical role in the onset of the disease, modulation of disease progression, and response to treatment. At the moment, the recently launched version 3.0 of Human MicroRNA Disease Database (HMDD v3.0) reports that 194 miRNAs are dysregulated in OS that might be involved in proliferation, migration, invasion, and epithelial-mesenchymal transition of tumor cells. The balance between oncogene and tumor suppressor miRNAs has vital importance in the final fate of the cell behaviors in OS. Additionally, networks of miRNAs may act in concert to induce oncogenic or tumor-suppressing properties during the initiation or the progression of OS. Up or down-regulation of these miRNAs affect the status of the disease during or after therapy. To date, over 40 miRNAs have been identified in OS disease that possess oncogenic or tumor-suppressing properties, and treatment approaches are trying to establish a proper level of such miRNAs in favor of OS therapy. The role of miRNAs involved in the pathogenesis of OS and their therapeutic potential are the reference points in this review article.
Export Options
About this article
Cite this article as:
MicroRNAs Implications in the Onset, Diagnosis, and Prognosis of Osteosarcoma, Current Molecular Medicine 2021; 21 (7) . https://dx.doi.org/10.2174/1566524020999201203212824
DOI https://dx.doi.org/10.2174/1566524020999201203212824 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Overview on the Role of miR-451 in Lung Cancer: Diagnosis, Therapy,
and Prognosis
MicroRNA The Anti-Cancer Charm of Flavonoids: A Cup-of-Tea Will Do!
Recent Patents on Anti-Cancer Drug Discovery Dietary Phytochemicals in Cancer Signalling Pathways: Role of miRNA Targeting
Current Medicinal Chemistry The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
Current Cancer Drug Targets NF-κB-IKKβ Pathway as a Target for Drug Development: Realities, Challenges and Perspectives
Current Drug Targets Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Morusin Inhibits Human Osteosarcoma via the PI3K-AKT Signaling Pathway
Current Pharmaceutical Biotechnology Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry Patents in Cancer Stem Cells
Recent Patents on Biomarkers Case Report of a Large Rhinolith Cast – A Frequently Missed Diagnosis
New Emirates Medical Journal Therapeutic Transfer of DNA Encoding Adenoviral E1A
Recent Patents on Anti-Cancer Drug Discovery The Effects of Trifluoromethylated Derivatives on Prostaglandin E<sub>2</sub> and Thromboxane A<sub>2</sub> Production in Human Leukemic U937 Macrophages
Medicinal Chemistry The Stem Cell Niche as a Pharmaceutical Target for Prevention of Skeletal Metastases
Anti-Cancer Agents in Medicinal Chemistry Profiling of Multiple Signal Pathway Activities by Multiplexing Antibody and GFP-Based Translocation Assays
Combinatorial Chemistry & High Throughput Screening Characteristic Alterations of Nuclear Structure and Chromatin Organisation of Cancer Cells Addressed by Proteome Analysis**
Current Proteomics Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Clinical-Grade Oncolytic Adenovirus Purification Using Polysorbate 20 as an Alternative for Cell Lysis
Current Gene Therapy Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation
Current Pharmacogenomics and Personalized Medicine The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Reverse Screening Bioinformatics Approach to Identify Potential Anti Breast Cancer Targets Using Thymoquinone from Neutraceuticals Black Cumin Oil
Anti-Cancer Agents in Medicinal Chemistry